Literature DB >> 31805908

Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.

Christina Sze1,2, Efrat Tsivian3, Kae Jack Tay3,4, Ariel A Schulman3, Leah G Davis3, Rajan T Gupta3,5, Thomas J Polascik3.   

Abstract

BACKGROUND: Due to their location away from the nerve bundles, anterior prostate cancers (APC) represent a rational target for image-guided cryoablation. This report describes the feasibility and short-term outcomes of anterior focal cryosurgery.
METHODS: A retrospective review between 2012 and 2016 of patients with clinically localized APC treated with anterior gland cryoablation was performed. Descriptive statistics were used to report: age, PSA, prostate volume, prostate cancer grade group (PGG), median time to follow-up, and changes in functional status measured with the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF-5) score.
RESULTS: A total of 17 patients underwent anterior focal cryoablation with a median follow-up of 15 months. Median age and PSA at diagnosis were 67 years and 8.7 ng/mL. Pre-operative PGG1 was identified in 12 (71%) men and PGG2 in 5 (29%) men. Median (IQR) lesion volume was 2 mL(0.86, 3.1). Preoperative median IIEF-5 and IPSS scores were 19.5 and 5, and decreased to 19 and 4, post-operatively. All patients remained continent with no change in sexual function. All post-procedure targeted biopsies of the treated cancers were negative.
CONCLUSION: Our pilot study demonstrates the feasibility of treating APCs with image-guided targeted focal cryoablation as a good balance between short-term oncologic control and near complete preservation of genitourinary function. Further follow-up is necessary to examine the potential benefits long-term.

Entities:  

Keywords:  Anterior gland; Continence; Erectile function; Focal cryoablation; Prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31805908      PMCID: PMC6896720          DOI: 10.1186/s12894-019-0562-5

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  26 in total

Review 1.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

Review 2.  Psychological aspects of prostate cancer: a clinical review.

Authors:  A De Sousa; S Sonavane; J Mehta
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-01-03       Impact factor: 5.554

3.  Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population.

Authors:  Melissa H Mendez; Niccolo Maria Passoni; Julio Pow-Sang; J Stephen Jones; Thomas J Polascik
Journal:  J Endourol       Date:  2015-07-13       Impact factor: 2.942

4.  Anterior prostate cancer: is it more difficult to diagnose?

Authors:  S R J Bott; M P A Young; M J Kellett; M C Parkinson
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

5.  Anterior Prostate Cancer: Diagnostic Performance of T2-Weighted MRI and an Apparent Diffusion Coefficient Map.

Authors:  Hiroshi Shinmoto; Chiharu Tamura; Shigeyoshi Soga; Teppei Okamura; Akio Horiguchi; Tomohiko Asano; Tatsumi Kaji
Journal:  AJR Am J Roentgenol       Date:  2015-08       Impact factor: 3.959

Review 6.  Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer.

Authors:  Rajan T Gupta; Benjamin Spilseth; Nayana Patel; Alison F Brown; Jinxing Yu
Journal:  Abdom Radiol (NY)       Date:  2016-05

7.  Anterior tumors of the prostate: clinicopathological features and outcomes.

Authors:  J Mygatt; I Sesterhenn; I Rosner; Y Chen; J Cullen; T Morris-Gore; J Barton; A Dobi; S Srivastava; D McLeod; S A Brassell
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-12-03       Impact factor: 5.554

8.  Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy.

Authors:  Hikmat A Al-Ahmadie; Satish K Tickoo; Semra Olgac; Anuradha Gopalan; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.

Authors:  Jan P Radtke; Constantin Schwab; Maya B Wolf; Martin T Freitag; Celine D Alt; Claudia Kesch; Ionel V Popeneciu; Clemens Huettenbrink; Claudia Gasch; Tilman Klein; David Bonekamp; Stefan Duensing; Wilfried Roth; Svenja Schueler; Christian Stock; Heinz-Peter Schlemmer; Matthias Roethke; Markus Hohenfellner; Boris A Hadaschik
Journal:  Eur Urol       Date:  2016-01-19       Impact factor: 20.096

10.  Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.

Authors:  Maarten de Rooij; Simone Crienen; J Alfred Witjes; Jelle O Barentsz; Maroeska M Rovers; Janneke P C Grutters
Journal:  Eur Urol       Date:  2013-12-21       Impact factor: 20.096

View more
  3 in total

Review 1.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

Review 2.  The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.

Authors:  Heying Duan; Andrei Iagaru
Journal:  Cancer Imaging       Date:  2022-09-03       Impact factor: 5.605

3.  Prostate cancer grading, time to go back to the future.

Authors:  Lars Egevad; Brett Delahunt; David G Bostwick; Liang Cheng; Andrew J Evans; Troy Gianduzzo; Markus Graefen; Jonas Hugosson; James G Kench; Katia R M Leite; Jon Oxley; Guido Sauter; John R Srigley; Pär Stattin; Toyonori Tsuzuki; John Yaxley; Hemamali Samaratunga
Journal:  BJU Int       Date:  2020-11-27       Impact factor: 5.588

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.